Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
Open Access
- 1 November 1998
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 9 (11) , 1251-1253
- https://doi.org/10.1023/a:1008475122124
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric studyAnnals of Oncology, 1998
- Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancersAnti-Cancer Drugs, 1997
- Addition of oxaliplatin (Eloxatine®, LOHP) to the same leucovorin (LV) and 5 fluorouracil (5FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): Preliminary reportEuropean Journal Of Cancer, 1997
- Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinomaCancer, 1997
- Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinomaCancer, 1997
- Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancerEuropean Journal Of Cancer, 1997
- Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidinesAnnals of Oncology, 1996